Corporate ProfileTocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
NASDAQ GS TOCA (Common Stock)
$9.19 - 0.38
05/24/18 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)05/14/18
Tocagen Reports First Quarter 2018 Financial and Business Results05/10/18
Tocagen to Report First Quarter 2018 Financial Results on Thursday, May 1005/03/18
Thursday, June 21, 201810:00 a.m. PT
Tocagen Inc 2018 Annual Meeting of Stockholders